Comparing of Thermo Fisher Scientific Inc. (TMO) and Heska Corporation (NASDAQ:HSKA)

As Medical Laboratories & Research businesses, Thermo Fisher Scientific Inc. (NYSE:TMO) and Heska Corporation (NASDAQ:HSKA), are affected by compare. This especially applies to their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Thermo Fisher Scientific Inc. 24.36B 4.09 2.94B 6.84 34.68
Heska Corporation 129.42M 5.78 1.31M 0.97 101.65

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Thermo Fisher Scientific Inc. and Heska Corporation. Heska Corporation seems to has lower revenue and earnings compared to Thermo Fisher Scientific Inc. Business that currently has a lower P/E ratio means that it is the more affordable of the two businesses. Thermo Fisher Scientific Inc. is trading at a lower P/E ratio than Heska Corporation, indicating that it is currently more affordable of the two stocks.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific Inc. 12.07% 9.8% 4.6%
Heska Corporation 1.01% 1.2% 0.9%

Volatility & Risk

A 1.08 beta indicates that Thermo Fisher Scientific Inc. is 8.00% more volatile compared to Standard & Poor’s 500. Heska Corporation’s 36.00% less volatile than Standard & Poor’s 500 which is a result of the 0.64 beta.

Liquidity

The Current Ratio of Thermo Fisher Scientific Inc. is 1.8 while its Quick Ratio stands at 1.3. The Current Ratio of rival Heska Corporation is 2.4 and its Quick Ratio is has 1.3. Heska Corporation is better equipped to clear short and long-term obligations than Thermo Fisher Scientific Inc.

Dividends

$0.68 per share with a dividend yield of 0.27% is the annual dividend that Thermo Fisher Scientific Inc. pay. Heska Corporation does not pay a dividend.

Analyst Recommendations

The table shown features the ratings and recommendations for Thermo Fisher Scientific Inc. and Heska Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Thermo Fisher Scientific Inc. 0 2 5 2.71
Heska Corporation 0 0 0 0.00

The average price target of Thermo Fisher Scientific Inc. is $251.33, with potential upside of 1.59%.

Insider & Institutional Ownership

Thermo Fisher Scientific Inc. and Heska Corporation has shares held by institutional investors as follows: 90.4% and 91.5%. Thermo Fisher Scientific Inc.’s share held by insiders are 0.1%. Competitively, Heska Corporation has 3% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Thermo Fisher Scientific Inc. -5% -3.44% -0.05% 9.08% 27.72% 24.86%
Heska Corporation -5.46% -1.95% -8.41% -7.66% 19.91% 22.55%

For the past year Thermo Fisher Scientific Inc. has stronger performance than Heska Corporation

Summary

Thermo Fisher Scientific Inc. beats Heska Corporation on 12 of the 15 factors.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. Its Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems to support clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; and human leukocyte antigen typing and testing for organ transplant market. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Its Laboratory Products and Services segment offers controlled temperature technology products; sample preparation and preservation equipment; centrifugation products and biological safety cabinets; water analysis instruments and laboratory equipment; laboratory consumables; chemicals; and research and safety market channel, and biopharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.

Heska Corporation develops, manufactures, and markets advanced veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. It operates through two segments, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and IV pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus Chewable Tablets for the preventive treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels. The Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and independent third-party distributors, as well as trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.